From GlobeNewswire: 2025-02-12 10:43:00

Orchestra BioMed presented data at the THT 2025 Conference showing AVIM therapy improved diastolic dysfunction in hypertensive patients, reducing systolic blood pressure and favorably impacting cardiac function. The study analyzed data from the MODERATO II trial, demonstrating significant echocardiographic improvements in patients with diastolic dysfunction. AVIM therapy may offer a new approach to managing hypertension and preventing heart failure in high-risk populations. The therapy is compatible with standard dual-chamber pacemakers and has shown promising results in lowering blood pressure. The ongoing BACKBEAT global pivotal study aims to further evaluate the efficacy and safety of AVIM therapy.



Read more at GlobeNewswire: Orchestra BioMed Announces Data Demonstrating Favorable